These biomarkers are associated with lower prefrontal gamma-aminobutyric acid (GABA) levels, further supporting the link between MMP9/RAGE pathway activation, inhibitory and excitatory imbalances, and the clinical manifestations of schizophrenia [63,64]. The gene discussed is AGER; the disease is schizophrenia.